- Details
- Christopher Wallis and Zachary Klaassen review the NCCN clinical practice guidelines on prostate cancer. This discussion is the third part of their discussion of androgen deprivation therapy (ADT). Dr. Wallis begins this discussion with a conversation on intermittent vs continuous ADT for patients with prostate cancer. He examines the quality of life in conjunction with survival measurements. Abou...
|
- Details
- In this UroToday discussion between Zachary Klaassen and Christopher Wallis, the pair discuss the NCCN clinical practice guidelines in oncology, specifically looking at prostate cancer. This part of the conversation specifically looks at androgen deprivation therapy (ADT) for castration-naive disease. Dr. Klaassen begins by discussing the different categories that ADT has been categorized into rec...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a recently published paper, entitled, “ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma.” They discuss the basics of circulating tumor DNA (ctDNA). He specifically discusses how we can use ctDNA to identify molecularly, or microscopic, residual disease. The study shows that ctDNA-positive patients with adjuvant atezolizumab, after surgery...
|
- Details
- Zachary Klaassen and Christopher Wallis discuss the NCCN guidelines for castration-resistant prostate cancer (CRPC) updated in February of 2021. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toronto Zachary Klaassen, MD, MSc, Urologic Oncologist, Assistant Professor Surgery/Urology at the Medical College of Georgia at Augusta U...
|
- Details
- UroToday is introducing an in-depth look at the NCCN Guidelines on Prostate Cancer. Zachary Klaassen and Christopher Wallis Androgen Deprivation Therapy (ADT) is broken down into six subsections including ADT for clinically localized N0M0 disease, ADT for regional disease, palliative ADT, ADT for castration-naive disease, intermittent versus continuous ADT, and adverse events for traditional ADT....
|
- Details
- At the 2021 ASCO GU Cancers Symposium, Dr Robert Motzer and colleagues presented the results of the CLEAR study examining first-line lenvatinib and everolimus or lenvatinib and pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma and concurrent with the presentation, CLEAR was published in the New England Journal of Medicine. In this UroToday Journal Club, Christopher Wall...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss a publication entitled Efficacy of Enzalutamide Plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: a Post Hoc Analyses of the ARCHES trial . The present study relies upon secondary analysis of the ARCHES trial, a multinational randomized controlled trial th...
|
- Details
- In this UroToday GU Oncology Journal Club, Christopher Wallis and Zachary Klaassen highlight a Journal of Clinical Oncology publication on a phase two open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma, progressing after platinum-based chemotherapy and checkpoint inhibitors. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With M...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss a retrospective analysis of randomized trials that suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men, a prospective study of abiraterone acetate plus prednisone to explore outcomes by race. The goal of this study was to first demonstrate the feasibili...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the first-in-human phase 1 study of belzutifan (MK-6482), a potent, selective small molecule inhibitor of Hypoxia-inducible factor-2α (HIF-2α). HIF-2α is a transcription factor that frequently accumulates in clear cell renal cell carcinoma (ccRCC), resulting in the constitutive activation of genes involved in carcinogen...
|
